Litigation Details for Intercept Pharmaceuticals, Inc. v. Apotex Inc. (D. Del. 2020)

Intercept Pharmaceuticals, Inc. v. Apotex Inc. (D. Del. 2020)

Docket		Date Filed	2020-08-21
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,047,117; 10,052,337; 10,174,073
Link to Docket	External link to docket

Details for Intercept Pharmaceuticals, Inc. v. Apotex Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-21	142	Order - -Memorandum and Order	terms of U.S. Patent Nos. 9,238,673 (“the ’673 Patent”), 10,047,117 (“the ’117 Patent”), 10,174,073 …of the ’673 Patent, the ’117 Patent, the ’337 Patent, the ’349 Patent, and the ’549 Patent are construed…10,174,073 (“the ’073 Patent”), 10,052,337 (“the ’337 Patent”), 10,751,349 (“the ’349 Patent”), and 10,758,549… matter” (’337 Patent, claims 1–8; ’349 Patent, claims 1, 19; ’549 Patent, …meaning (’337 patent, claim 11; ’349 patent, claim 4; ’549 patent, claims 12, 23	External link to document

Intercept Pharmaceuticals v. Apotex (1:20-cv-01105-MN): Litigation Summary, Case Posture, and IP Risk for Generic Launch

Last updated: July 30, 2026

Intercept Pharmaceuticals, Inc. v. Apotex Inc., No. 1:20-cv-01105-MN (D. Del.) is a Hatch-Waxman patent infringement dispute tied to Intercept’s Ocaliva (obeticholic acid). The docket reflects a Paragraph IV-style infringement posture against Apotex, with claims aimed at Orange Book-listed IP protecting the commercial drug and/or approved method(s) of use. The case’s commercial relevance is tied to launch timing, damages exposure, and the scope of any settlement that blocks or conditions Apotex’s entry.

What claims were asserted in Intercept Pharmaceuticals, Inc. v. Apotex Inc. (1:20-cv-01105-MN)?

Answer: The case is a patent infringement action brought by Intercept against Apotex over a generic version of obeticholic acid (Ocaliva). The asserted patents correspond to one or more Orange Book listings for the approved drug, with typical Hatch-Waxman infringement theories (literal infringement and/or infringement under the doctrine of equivalents) tied to manufacture, use, sale, offer for sale, and/or importation of the proposed generic product.

What product does the litigation track?

• Drug: Ocaliva (obeticholic acid)
• Regulatory framework: Hatch-Waxman (likely Paragraph IV given the case structure and typical Del. generic litigation patterns)
• Alleged conduct: manufacture, use, offer for sale, sale, and/or importation of an accused generic product prior to patent expiration

What infringement theories are generally pleaded in this posture?

• Direct infringement (typical for small-molecule generics)
• Induced and/or contributory infringement (often included)
• Specific performance-based infringement allegations tied to the product profile claimed in the patents

Which Intercept patents are involved in 1:20-cv-01105-MN?

Answer: The litigation targets one or more patents listed in the Orange Book for Ocaliva (obeticholic acid). The court record in this matter indicates asserted patent identifiers aligned to Intercept’s commercial IP estate.

Why the Orange Book listing matters

Orange Book listings anchor the Hatch-Waxman reference for:

• Whether the case is tethered to specific patent claims
• Whether the infringement case is framed around the NDA’s approved indications or formulation/method claims

IP estate segmentation (how these disputes are usually constructed)

The Ocaliva estate commonly includes:

• Composition/formulation patents (drug substance, polymorphs, composition claims)
• Method-of-use patents (dosing/indication claims)
• Manufacturing/processing patents (less frequently but possible)

Practical consequence: the asserted patent category affects what design-arounds Apotex can pursue and the likelihood of settlement because formulation and method-of-use claims differ in “entry risk” and generic substitution leverage.

What was the procedural posture in 1:20-cv-01105-MN (filing, motions, and scheduling)?

Answer: The action was filed in 2020 in the District of Delaware and proceeds through early-stage case management and typical Hatch-Waxman motion practice. The posture is consistent with infringement litigation focused on claim construction, dispositive motions, and a schedule tied to the statutory 30-month stay framework (where applicable).

Key milestone types that shape Hatch-Waxman timelines

• Initial complaint and service
• Responsive pleadings
• Patent infringement contentions
• Claim construction (Markman) schedule
• Dispositive motions (validity/enforceability)
• Pretrial and trial (if not settled)

Why posture affects settlement probability

• Early claim construction and expert discovery increase settlement leverage
• Dispositive motion outcomes can narrow claims or eliminate them, changing the risk profile for both parties

What is the claim-construction and validity risk profile for Apotex in 1:20-cv-01105-MN?

Answer: In Intercept v. Apotex-type disputes for small-molecule generics, the typical risk stack for a generic defendant includes:

• Narrow claim construction arguments that still read on generic manufacturing/test data
• Invalidity challenges (anticipation, obviousness, lack of written description/enablement, indefiniteness)
• Enforceability defenses (inequitable conduct, prosecution history estoppel) where pled

The two axes that drive outcomes

1. Validity strength of asserted claims
   • Prior art landscape and teaching away
   • Claim definiteness and scope relative to the accused product
2. Infringement evidence
   • Product composition and specifications
   • Comparative performance/assay data where relevant to formulation or method claims

What does the settlement landscape look like in Intercept v. Apotex (1:20-cv-01105-MN)?

Answer: The case is a Hatch-Waxman framework in which settlements are common and frequently include:

• A dismissal with prejudice of some or all claims
• A covenant not to sue through a defined date
• License or royalty terms in exchange for earlier or conditional entry
• Product design-around commitments
• Mutual releases and specified import/manufacture restrictions

How to interpret settlement in commercial terms

• Early entry risk: whether Apotex’s launch was blocked or permitted ahead of the latest expiration
• Design-around leverage: whether Intercept demanded changes that affect manufacturing scale or testing
• Damages: whether earlier supply was compensated via license terms

When does Intercept’s Ocaliva patent exclusivity end relative to generic entry risk?

Answer: Generic entry risk is tied to the last-to-expire asserted patent(s) for the NDA. In this case, the exclusivity and patent calendar determine the “hard stop” date for Apotex or the earliest lawful market entry date if a settlement authorizes launch.

Practical exclusivity mechanics that control entry

• Statutory patent expiration (utility patents)
• Any patent term adjustments and extensions (where applicable)
• Exclusivity periods attached to the NDA approval (if relevant)
• Potential pediatric exclusivity (if any)
• Any 30-month stay dynamics tied to the first Paragraph IV notice (if triggered in the underlying ANDA)

How strong is Intercept’s patent estate for obeticholic acid against generic challenges like Apotex?

Answer: Intercept’s enforcement posture in the Hatch-Waxman venue signals that the Orange Book-listed patents are regarded as protectable claim coverage around Ocaliva’s commercial reality. The strength evaluation for Apotex in this case turns on claim scope relative to the generic’s product specification and the validity defensibility of those claims over the relevant prior art.

Strength markers that typically favor the NDA holder

• Claims drafted to read on standard generic manufacturing and composition
• Supported priority disclosures that map to claim limitations
• Prior art that does not disclose all elements in combination

Strength markers that typically favor the generic

• Broad claims that fail novelty or obviousness
• Written description or enablement vulnerabilities
• Indefiniteness that collapses infringement-to-invalidity defenses

What defenses and counterclaims are typical for a Hatch-Waxman defendant here?

Answer: Apotex’s likely litigation posture includes:

• Non-infringement (product does not meet claim limitations)
• Invalidity (anticipation/obviousness)
• Invalidity/enforceability issues (as pled)
• Potential counterclaims tied to declaratory judgment or invalidity findings

Common motion targets

• Summary judgment on infringement
• Summary judgment on invalidity/unenforceability
• Exclusion of expert testimony
• Claim construction disputes that decide dispositive issues

What is the commercial impact of 1:20-cv-01105-MN for Apotex and competitors?

Answer: The case affects:

• Timing of Apotex’s ability to market a generic obeticholic acid product
• Potential settlement licensing terms that define commercial entry economics
• Competitive positioning for other ANDA filers tied to the same Orange Book patents

Market leverage points

• If Intercept wins on a dispositive basis, entry can be delayed past expiration
• If invalidation occurs, additional defendants gain leverage and settlement pressure increases
• If the case is settled, the agreement can become a template for global resolution strategies

Which companies are likely aligned with or affected by this case (co-defendants, related matters)?

Answer: While the caption names Apotex as defendant, these matters typically cluster by:

• Other ANDA filers challenging the same Orange Book patents
• Additional cases between the same NDA holder and multiple generic entrants
• Co-pending proceedings that share the same asserted patent family or claim constructions

Key takeaways

• Case identity: Intercept Pharmaceuticals, Inc. v. Apotex Inc., No. 1:20-cv-01105-MN (D. Del.) is an Orange Book-tethered Hatch-Waxman infringement dispute involving Ocaliva (obeticholic acid).
• Core dispute driver: the asserted patents protect aspects of the approved product (composition/formulation and/or method of use), and Apotex faces both infringement and validity challenges typical of Paragraph IV litigation.
• Commercial control lever: the last expiring asserted patent(s) and any settlement terms define the earliest lawful entry date and the damages/royalty economics.
• Settlement is the main off-ramp: as in most Hatch-Waxman cases, resolution is typically achieved via covenants/licensing and entry scheduling, reducing trial risk.

FAQs

1) What is a Paragraph IV filing and how does it shape this kind of Intercept v. Apotex litigation?
A Paragraph IV notice asserts non-infringement and/or invalidity of the Orange Book-listed patents, triggering infringement litigation and potentially a 30-month stay framework depending on the notice timing and regulatory posture.

2) How do method-of-use patents versus formulation patents change generic design-around strategy?
Method-of-use claims constrain prescribing/dosing behavior and indication scope, while formulation claims constrain excipients, polymorph selection, composition, and manufacturing controls.

3) What evidence most often decides infringement in small-molecule Hatch-Waxman cases?
Drug substance and product specifications, manufacturing/test data, and expert mapping of claim limitations to measurable attributes of the accused product.

4) Can a generic launch occur before the last asserted patent expires?
Yes, if there is a settlement or if patents are invalidated/withdrawn such that fewer barriers remain. Otherwise, entry generally remains blocked by the unexpired enforceable patents.

5) How does the District of Delaware venue affect Hatch-Waxman timing?
Delaware’s patent docket is structured for early claim construction and intensive scheduling, which tends to accelerate case narrowing toward dispositive outcomes or settlement.

References

1. Intercept Pharmaceuticals, Inc. v. Apotex Inc., No. 1:20-cv-01105-MN (D. Del.).